Plasma DNA methylation detection for early screening, diagnosis, and monitoring of esophageal adenocarcinoma and squamous cell carcinoma

Figure 3 Quantitative analysis of SEPTIN9, SHOX2, RNF180, and EPO methylation in plasma specimens of controls (n = 102) and patients with esophageal adenocarcinoma (n = 33) and squamous cell carcinoma (n = 177). A-D: Quantitative analysis of SEPTIN9 (A), SHOX2 (B), RNF180 (C), and EPO (D) methylation in esophageal adenocarcinoma, squamous cell carcinoma (SCC), and controls. No significant differences were observed in the positive rates of SHOX2, RNF180, SEPTIN9, and EPO methylation in esophageal cancer patients with SCC and adenocarcinoma, while they exceeded those of healthy controls and benign patients. ^aP < 0.05.